MYD88 and COVID-19: Given that overall imbalance in host immune system with inflammatory diseases including toxic shock, COPD as well as COVID-19 which is more to do with controlling inflammation, MyD88-targeted therapy would likely provide an advantage in treating severe inflammatory responses.